Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...
NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...
4d
Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...
Revenue exceeded analyst estimates by 32%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Looking ahead, ...
Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
6d
Nektar Therapeutics (NKTR) extends its cash runway into 2026 with strategic divestitures, despite ongoing financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback